Literature DB >> 27052221

[Insulin therapy of diabetes].

Monika Lechleitner1, Michael Roden2, Raimund Weitgasser3, Bernhard Ludvik4, Peter Fasching5, Friedrich Hoppichler6, Alexandra Kautzky-Willer4, Guntram Schernthaner7, Rudolf Prager8, Thomas C Wascher9.   

Abstract

Hyperglycemia contributes to morbidity and mortality in patients with diabetes. Thus, reaching treatment targets with regard to control of glycemia is a central goal in the therapy of diabetic patients. The present article represents the recommendations of the Austrian Diabetes Association for the practical use of insulin according to current scientific evidence and clinical studies.

Entities:  

Keywords:  Dosage; Insulin therapy; Regimen

Mesh：

Substances：

Year:  2016        PMID： 27052221     DOI： 10.1007/s00508-015-0925-1

Source DB:  PubMed          Journal:  Wien Klin Wochenschr        ISSN： 0043-5325            Impact factor:   1.704


  44 in total

1.  New insulin glargine 300 Units · mL-1 provides a more even activity profile and prolonged glycemic control at steady state compared with insulin glargine 100 Units · mL-1.

Authors:  Reinhard H A Becker; Raphael Dahmen; Karin Bergmann; Anne Lehmann; Thomas Jax; Tim Heise
Journal:  Diabetes Care       Date:  2014-08-22       Impact factor: 19.112

2.  Intensive diabetes treatment and cardiovascular disease in patients with type 1 diabetes.

Authors:  David M Nathan; Patricia A Cleary; Jye-Yu C Backlund; Saul M Genuth; John M Lachin; Trevor J Orchard; Philip Raskin; Bernard Zinman
Journal:  N Engl J Med       Date:  2005-12-22       Impact factor: 91.245

Review 3.  Management of diabetes mellitus: is the pump mightier than the pen?

Authors:  John C Pickup
Journal:  Nat Rev Endocrinol       Date:  2012-02-28       Impact factor: 43.330

4.  Concomitant oral antihyperglycemic agent use and associated treatment outcomes after initiation of insulin therapy.

Authors:  William H Herman; John B Buse; Richard F Arakaki; Kathleen M Dungan; Honghua H Jiang; Jennie G Jacobson; Jessie L Fahrbach
Journal:  Endocr Pract       Date:  2011 Jul-Aug       Impact factor: 3.443

5.  Management of hyperglycemia in type 2 diabetes, 2015: a patient-centered approach: update to a position statement of the American Diabetes Association and the European Association for the Study of Diabetes.

Authors:  Silvio E Inzucchi; Richard M Bergenstal; John B Buse; Michaela Diamant; Ele Ferrannini; Michael Nauck; Anne L Peters; Apostolos Tsapas; Richard Wender; David R Matthews
Journal:  Diabetes Care       Date:  2015-01       Impact factor: 19.112

6.  Effect of intensive therapy on the microvascular complications of type 1 diabetes mellitus.

Authors: 
Journal:  JAMA       Date:  2002-05-15       Impact factor: 56.272

7.  Three-year efficacy of complex insulin regimens in type 2 diabetes.

Authors:  Rury R Holman; Andrew J Farmer; Melanie J Davies; Jonathan C Levy; Julie L Darbyshire; Joanne F Keenan; Sanjoy K Paul
Journal:  N Engl J Med       Date:  2009-10-22       Impact factor: 91.245

8.  Dapagliflozin in patients with type 2 diabetes receiving high doses of insulin: efficacy and safety over 2 years.

Authors:  J P H Wilding; V Woo; K Rohwedder; J Sugg; S Parikh
Journal:  Diabetes Obes Metab       Date:  2013-08-29       Impact factor: 6.577

Review 9.  Insulin monotherapy versus combinations of insulin with oral hypoglycaemic agents in patients with type 2 diabetes mellitus.

Authors:  A N Goudswaard; N J Furlong; G E H M Rutten; R P Stolk; G D Valk
Journal:  Cochrane Database Syst Rev       Date:  2004-10-18

10.  QTc interval prolongation is independently associated with severe hypoglycemic attacks in type 1 diabetes from the EURODIAB IDDM complications study.

Authors:  Gabriella Gruden; Sara Giunti; Federica Barutta; Nish Chaturvedi; Daniel R Witte; Marinella Tricarico; John H Fuller; Paolo Cavallo Perin; Graziella Bruno
Journal:  Diabetes Care       Date:  2011-11-28       Impact factor: 19.112
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.